# Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Study · id `cardio:ct-nct01351675` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01351675](<https://clinicaltrials.gov/study/NCT01351675>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01351675

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2185 participants.

## Technical summary

Registry record NCT01351675. Randomized; quadruple masking; primary purpose treatment. Start 2011-06-30 (actual); primary completion 2012-10-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2185 participants (enrolled count; ClinicalTrials.gov record NCT01351675, source copy `cardio:ctgov-nct01351675-2025-05-29`, retrieved 2026-10-26)
- Started: 2011-06-30 (actual) (ClinicalTrials.gov record NCT01351675, source copy `cardio:ctgov-nct01351675-2025-05-29`, retrieved 2026-10-26)
- Primary completion: 2012-10-31 (actual) (ClinicalTrials.gov record NCT01351675, source copy `cardio:ctgov-nct01351675-2025-05-29`, retrieved 2026-10-26)
- Completion: 2012-12-31 (actual) (ClinicalTrials.gov record NCT01351675, source copy `cardio:ctgov-nct01351675-2025-05-29`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01351675-2025-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Acronym: BEACON
- Condition: Renal Insufficiency, Chronic
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo
- Intervention (Drug): Bardoxolone Methyl: 20 mg
- Lead sponsor: Biogen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Biogen (`cardio:org-biogen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (`cardio:pubmed-24206459`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 75b38e8e7ed0acae8efede32716cfcaa6d9d68119a30c86f13610926a8108594
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
